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Metabolic enzymes are involved in the activation/deactivation of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyiridine (MPTP)
neurotoxin and its naturally occurring analogs 2-methyltetrahydro-𝛽-carbolines. The metabolic profile and biotransformation
of these protoxins by three enzymes, monoamine oxidase (MAO), cytochrome P450, and heme peroxidases (myeloperoxidase
and lactoperoxidase), were investigated and compared. The metabolite profile differed among the enzymes investigated. MAO
and heme peroxidases activated these substances to toxic pyridinium and 𝛽-carbolinium species. MAO catalyzed the oxidation
of MPTP to 1-methyl-4-phenyl-2,3-dihydropyridinium cation (MPDP+), whereas heme peroxidases catalyzed the oxidation of
MPDP+ to 1-methyl-4-phenylpyridinium (MPP+) and of 2-methyltetrahydro-𝛽-carboline to 2-methyl-3,4-dihydro-𝛽-carbolinium
cation (2-Me-3,4-DH𝛽C+). These substances were inactivated by cytochrome P450 2D6 through 𝑁-demethylation and aromatic
hydroxylation (MPTP) and aromatic hydroxylation (2-methyltetrahydro-𝛽-carboline). In conclusion, the toxicological effects of
these protoxins might result from a balance between the rate of their activation to toxic products (i.e., 𝑁-methylpyridinium-
MPP+ and MPDP+- and 𝑁-methyl-𝛽-carbolinium—𝛽C+—) by MAO and heme peroxidases and the rate of inactivation (i.e., 𝑁-
demethylation, aromatic hydroxylation) by cytochrome P450 2D6.
1. Introduction
The causative factors of neurodegenerative diseases such
as Parkinson’s disease (PD) remain unknown, although the
involvement of environmental and/or endogenous neurotox-
ins is being increasingly considered [1–3]. Exposure to 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a con-
taminant found in “synthetic heroin,” produces neurotoxi-
city in humans, and this neurotoxin is commonly used to
generate experimental parkinsonism in animalmodels [4–7].
MPTP crosses the blood-brain barrier and is bioactivated
enzymatically to give 1-methyl-4-phenylpyridinium (MPP+)
[1, 8, 9], which is selectively uptaken into dopaminergic
cells via dopamine-activated transporter (DAT) andproduces
inhibition of mitochondrial complex I, energy depletion,
and cell death [8] (Figure 1). Besides its use in experimental
models of neurotoxicity, the toxic outcome caused by MPTP
is a matter of investigation due to the differences in response
among experimental models [10, 11]. This might result from
a change in the balance between the rate of metabolism to
toxic products (MPP+ and MPDP+) (activation) and the rate
of detoxification (inactivation) [12–16]. MPTP is metabolized
by enzymes such as cytochrome P450, and this could affect
the outcome of this neurotoxin [12, 14, 17–19].
Humans are not usually exposed to MPTP but are
exposed to some structural analogs such as the 𝛽-carboline
alkaloids [20–22]. 𝛽-Carbolines appear in foods and are
absorbed into the human body and brain, where they may
exert psychopharmacological and toxic effects [23–28].These
compounds might follow a toxicological pattern similar
to that of MPTP (Figure 1). Firstly, these alkaloids could
be bioactivated to N-methyl derivatives and then oxi-
dized (aromatized) to pyridinium-like 𝛽-carbolinium species
[15, 20, 21, 29]. 𝛽-Carbolinium (𝛽C+) species share several
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Figure 1: Activation of MPTP to the directly acting neurotoxin MPP+, which is uptaken by dopaminergic cells via DAT (dopamine active
transporter) and produces neurotoxicity and cell death. 𝛽-Carbolinium cations (𝛽C+) are toxic analogs of MPP+ that may arise from 2-
methyl-1,2,3,4-tetrahydro-𝛽-carbolines.
functional and toxicological properties with 1-methyl-4-phe-
nylpyridinium (MPP+), which is the metabolite involved in
MPTP neurotoxicity [30–32], and were postulated as poten-
tial slow-acting neurotoxins [33, 34]. Remarkably,N-methyl-
𝛽-carbolinium species such as N-methylnorharmanium (2-
Me-𝛽C+) and 2,9-dimethylnorharmanium (2,9-diMe-𝛽C+)
have been detected in postmortemhuman brains [34–36] and
found in higher proportion in cerebrospinal fluid of patients
with neurodegenerative diseases (PD) [35].
The toxicological outcome ofMPTP and𝛽-carbolineswill
depend on the metabolic profile produced by key enzymes
leading to the activation/inactivation of these protoxins [21].
Therefore, studying the activation/inactivation (biotransfor-
mation) of MPTP and its naturally occurring analogs by
metabolic enzymes is a matter of current interest in order
to explain the toxicological features of these substances. It
could lead to the identification of the enzyme responsible
for activation and inactivation as well as the metabolites
produced, and it may also suggest interindividual differences.
In this regard, the purpose of this research was to study in a
comparative way themetabolic profile generated fromMPTP
and its naturally occurring analog 2-methyltetrahydro-𝛽-
carboline by three metabolic enzymes: monoamine oxidase
(MAO), heme peroxidase, and cytochrome P450 (2D6).
Monoamine oxidase (MAO) is a flavoenzyme located at the
outer membranes of mitochondria in the human brain and
peripheral tissues that catalyzes the oxidative deamination of
neurotransmitters and xenobiotic amines. MAO appears as
two isozymes, MAO-A and B, and plays an important role in
the central nervous system and peripheral organs [37].MAO-
A is involved in psychiatric conditions and depression and
MAO-B is implicated in neurodegenerative diseases [37–41].
The cytochrome P450 enzymes are mixed-function oxidases
involved in the metabolism of drugs and xenobiotics. In par-
ticular, the cytochrome P450 2D6 is present in the liver and
extrahepatic tissues and participates in the metabolism and
toxicity ofmany drugswith a basic nitrogen.This cytochrome
presents strong polymorphism, characterized by poor, inter-
mediate, extensive, and ultrarapid metabolizers, and it is
currently being considered in relation to neurodegenerative
diseases [17, 42–46]. Heme peroxidases participate in the oxi-
dation of endogenous substrates, drugs, and xenobiotics [47].
Mammalian peroxidases such as myeloperoxidase (MPO),
eosinophil peroxidase (EPO), and lactoperoxidase (LPO) are
found in neutrophils, eosinophils, and secretory cells of the
exocrine glands and participate in antimicrobial and anti-
inflammatory processes. MPO occurs in activated microglia
at sites of degenerative diseases [48–50]. Peroxidases in the
substantia nigra may produce toxic substances and might be
involved in PD and neurodegeneration [51, 52].
2. Material and Methods
2.1. Chemicals and Enzymes. 1-Methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine (MPTP) hydrochloride (caution: MPTP is a
neurotoxin and should be handled with appropriate precau-
tions), 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+)
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perchlorate, 1-methyl-4-phenylpyridinium (MPP+) iodide, 4-
phenyl-1,2,3,6-tetrahydropyridine hydrochloride (PTP), and
NADPH were from Sigma-Aldrich (St. Louis, MO, USA). 2-
Methyl-1,2,3,4-tetrahydro-𝛽-carboline hydrochloride (2-Me-
TH𝛽C), 2-methyl-3,4-dihydro-𝛽-carbolinium chloride (2-
Me-3,4-DH𝛽C+), 2-methyl-𝛽-carbolinium iodide (2-Me-
𝛽C+), and 4-(4󸀠-hydroxyphenyl)-1-methyl-1,2,3,6-tetrahy-
dropyridine hydrochloride (MPTP-OH) were obtained pre-
viously [14–16]. Humanmonoamine oxidases (MAO-A and -
B) were obtained from BDGentest Co. (Woburn, MA, USA).
Microsomes containing recombinant human cytochrome
P450 2D6∗1+cytochrome P450 oxidoreductase produced
frombaculovirus infected-insect cells were obtained fromBD
Gentest Co. (Woburn, MA, USA). Bovine lactoperoxidase
(LPO) and human myeloperoxidase (MPO) were obtained
from Sigma and Calbiochem (Merck), respectively, and
the concentration in the assays is determined using the
extinction coefficients of Soret bands [53].
2.2. Enzyme Biotransformation and Metabolic Profile
2.2.1. MAO Enzymes. 0.2mL reaction mixtures in 75mM
buffer phosphate (pH 7.4) containing human MAO-A or
-B (0.01–0.2mg/mL protein) and MPTP (50, 250𝜇M) or
2-methyl-1,2,3,4-tetrahydro-𝛽-carboline (50, 250 𝜇M) were
incubated (37∘C, 40min); the reaction was stopped by the
addition of 2N NaOH (75𝜇L) and 70% perchloric acid
(25 𝜇L) subsequently centrifuged (9000 rpm, 5∘C), and 20 𝜇L
of the supernatant injected into the HPLC. The metabolic
profile was analyzed by HPLC-DAD, and the metabolites
identified by mass spectrometry (ESI). Incubations were
performed at least in duplicate.
2.2.2. Cytochrome P450 2D6. 0.2mL reaction mixtures in
75mM phosphate buffer (pH 7.4) containing human cyto-
chrome P450 2D6 (7 pmol P450) and MPTP (50, 250 𝜇M) or
2-methyl-1,2,3,4-tetrahydro-𝛽-carboline (50, 250 𝜇M), and
NADPH (1mM)were incubated at 37∘C, 25min.The reaction
was stopped with a mixture of methanol and perchloric
acid (1 : 1) (50𝜇L), centrifuged at 10000 rpm for 10min,
and 5∘C, and 20𝜇L of the supernatant injected into the
HPLC. The metabolic profile was analyzed by HPLC-DAD,
and the metabolites identified by mass spectrometry (ESI).
Incubations were performed at least in duplicate.
2.2.3. Heme Peroxidases. 0.5mL reaction mixtures in 50mM
phosphate buffer (pH 7), containing lactoperoxidase (LPO)
(0.18 𝜇M) ormyeloperoxidase (MPO) (0.013 𝜇M), andMPTP
(50, 250 𝜇M), MPDP+ (50, 250 𝜇M) or 2-methyl-1,2,3,4-tet-
rahydro-𝛽-carboline (50, 250 𝜇M), and H
2
O
2
(25 𝜇M) were
incubated at 37∘C, 40min. Following the addition ofHClO
4
+
methanol (1/1) (10% v/v of reaction volume), the tubes
were centrifuged at 10000 rpm, 10min, and 20 𝜇L of the
supernatant injected into the HPLC. The metabolic profile
was analyzed by HPLC-DAD, and the metabolites identified
by mass spectrometry (ESI). Incubations were performed at
least in duplicate.
2.2.4. RP-HPLC Chromatographic Analysis and Mass Spec-
trometry. Thechromatographic analysis of the reaction prod-
ucts from enzyme incubations was performed by RP-HPLC
with uv-DAD and fluorescence detection using anHPLC 1050
(Hewlett Packard) with a Diode Array Detector (DAD) and
a 1046A-fluorescence detector [14, 15]. A 150mm × 3.9mm,
4 𝜇m, Nova-pak C18 column (Waters, Milford, MA, USA)
was used for chromatographic separation. Chromatographic
conditions were buffer A: 50mM ammonium phosphate
buffer (pH 3 for MAO and peroxidase assays or pH 5.5 for
cytochrome P450 2D6) and buffer B: 20% of A in acetonitrile.
Gradient was programmed from 0% (100% A) to 32% B at
8min and 90% B at 15min. The flow rate was 1mL/min, the
column temperature was 40∘C, and the injection volume was
20𝜇L. Absorbance detection was set at 355 nm for analysis
of dehydrogenation products such as MPDP+ and 2-methyl-
3,4-dihydro-𝛽-carbolinium species (2-Me-DH𝛽C+); 280 nm
for analysis of MPP+; 254 nm for the analysis of 2-methyl-
𝛽-carbolinium cation; 280 nm for 2-methyltetrahydro-𝛽-
carboline (2-Me-TH𝛽C) and its metabolites, 243 nm for PTP,
and 254 nm forMPTP-OH. Calibration curves of absorbance
versus concentration were constructed for each metabolite.
Identification of metabolites was done by UV (DAD spectra)
fluorescence and coelution with authentic standards. Confir-
mation of the identity was performed with HPLC-ESI-mass
spectrometry [14, 15]. For that, separation was accomplished
on a 2.1 × 150mm Zorbax SB-C18 3.5 𝜇m column by using
an HPLC-MSD Series 1100 (Hewlett Packard, Santa Clara,
CA, USA) working under electrospray ionization positive-
ion mode. Eluents: (A) formic acid (0.5%), (B) formic acid
0.5% in acetonitrile; 80% B in 30min, flow: 0.25mL/min,
cone voltage: 70V, and mass range: 50–600 amu.
3. Results and Discussion
The activation and inactivation of MPTP neurotoxin and 2-
methyltetrahydro-𝛽-carboline protoxin occur with the par-
ticipation of key metabolic enzymes. This research studied
and compared the metabolic profile generated from these
substances by human monoamine oxidase, human cyto-
chrome P450 2D6, and heme peroxidases (Figure 2). Human
MAO enzymes (MAO-B) oxidized MPTP to give MPDP+
and MPP+ (Figure 3(a)). The main metabolite arising from
MAO andMPTP was MPDP+, whereas MPP+ was produced
through subsequent oxidation of MPDP+ (Figure 4(a)). As
the pyridinium species are the directly acting neurotoxins
in vivo, the oxidation by MAO is considered a key route for
the bioactivation of MPTP (Figure 2) [8]. Indeed, inhibitors
of MAO-B usually protect against this neurotoxin and can
be useful as neuroprotectants [37, 40, 41, 54, 55]. Although
human MAO-A was also able to oxidize MPTP in vitro as
well, a number of studies have shown thatMAO-B is themain
isoform involved in this oxidation [54–57].
The neurotoxin MPTP was metabolized by the cyto-
chrome P450 2D6 (Figure 3(b)). Twomajor metabolites were
4-(4󸀠-hydroxyphenyl)-1-methyl-1,2,3,6-tetrahydropyridine
(MPTP-OH) (aromatic hydroxylation) and 4-phenyl-1,2,3,6-
tetrahydropyridine (PTP) (N-demethylation) (Figure 4(b)).
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Figure 3: HPLC chromatograms ofMPTP oxidized by humanMAO-B (a) andMPTP oxidized by human cytochrome P450 2D6 (b). Enzyme
assays and chromatographic conditions were as indicated in experimental section.
In addition, the cytochrome P450 2D6 oxidized MPTP to
give minor amounts of MPDP+ and MPP+, although this
conversion was of lower efficiency compared with MAO
(Figure 4(c)). On the other hand, two heme peroxidases
(lactoperoxidase and myeloperoxidase) were unable to oxi-
dize MPTP to pyridinium species in the presence of H
2
O
2
,
indicating that MPTP was not a substrate of these kinds of
oxidative enzymes. Interestingly, however, these peroxidases
accelerated the oxidation of MPDP+ to MPP+ (Figure 6(c)).
Although MPDP+ could be auto oxidized or disproportion-
ated to giveMPP+ [15, 58] as reported in Figure 2, peroxidases
increased this oxidation when compared to controls. Then,
activation of the MPDP+ to the directly acting neurotoxin
MPP+ could be facilitated by heme peroxidases, and this
might have further implications for the neurotoxicity of this
and related substances (Figure 2).
In a search for analogies with MPTP, the naturally
occurring 𝛽-carboline 2-methyltetrahydro-𝛽-carboline was
metabolized by the former enzymes (Figure 2). HumanMAO
enzymes (MAO-A or -B) did not afford any detectable
metabolites of oxidation (i.e., 𝛽-carbolinium species). There-
fore, MPTP and its 𝛽-carboline analogs behaved differ-
ently regarding themetabolism byMAO, suggesting that they
differ in the activation pathway (Figure 2). Instead, the cyto-
chrome P450 2D6 was able to metabolize the tetrahydro-
𝛽-carboline that was hydroxylated to two metabolites identi-
fied as 6-hydroxy-2-methyl-1,2,3,4-tetrahydro-𝛽-carboline
(6-OH-2-Me-TH𝛽C) and 7-hydroxy-2-methyl-1,2,3,4-tetra-
hydro-𝛽-carboline (7-OH-2-Me-TH𝛽C) (Figures 5(a) and
6(a)). These polar metabolites could be considered detox-
ification metabolites, and, in that case, the cytochrome
P450 2D6 can participate in an inactivation route of
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2-methyltetrahydro-𝛽-carboline, in a similar way to MPTP.
On the other hand, 2-methyltetrahydro-𝛽-carboline was oxi-
dized in a reaction catalyzed by heme peroxidases in the pres-
ence of H
2
O
2
(Figure 5(b)). This tetrahydro-𝛽-carboline was
oxidized by lactoperoxidase and myeloperoxidase to the cor-
responding 2-methyl-3,4-dihydro-𝛽-carbolinium cation (2-
Me-3,4-DH𝛽C+) (Figure 6(b)) and traces detected of the fully
aromatic 𝛽-carbolinium cation (2-methyl-𝛽-carbolinium
cation). The 𝛽-carbolinium species are neurotoxic sub-
stances [30, 33], and therefore this oxidation may repre-
sent a new route of activation of naturally occurring 2-
methyltetrahydro-𝛽-carbolines, which could be of signifi-
cance for the toxicological fate of these substances (Figure 2).
These results agree with the ability of tetrahydro-𝛽-carbolines
to be oxidized to dihydro- and aromatic 𝛽-carbolines [27,
59] and also with the participation of these substrates in a
reduction of redox intermediates of peroxidases [53].
MPTP induces parkinsonism in humans and animal
models, whereas the 𝛽-carbolines were postulated as pos-
sible toxins involved in neurodegeneration [20]. As seen
in Figure 2, biochemical reactions leading to the activa-
tion/inactivation of these substances are critical for their
toxicological outcome. A so-called “activation” to toxic pyri-
dinium or 𝛽-carbolinium species is required for toxicity,
whereas an “inactivation”may influence the fate of these pro-
toxins in the body. Differences in the activation/inactivation
balance and consequently in the response to these substances
may arise from differences in the enzymes involved.The toxic
response to MPTP largely varies between species [7, 10, 11],
and this might result from differences in the expression and
activity of metabolic enzymes [49, 50, 60, 61] producing a
different ratio between toxic and inactive metabolites. The
results reported here indicate substantial differences among
the enzymes involved and profile (Figure 2). While MAO
enzymes were responsible for the activation of MPTP to give
toxic pyridinium species, heme peroxidases were activators
of 2-methyltetrahydro-𝛽-carbolines to pyridinium-like car-
bolinium toxins and MAO played no role. Although heme
peroxidases were not involved in the MPTP activation, these
enzymes catalyzed the oxidation step fromMPDP+ toMPP+.
Thus, heme peroxidases like myeloperoxidase may accelerate
the flow from MPDP+ (i.e., produced by MAO) to MPP+.
With these results in mind, peroxidases might play a role
in the bioactivation of these or related protoxins, resulting
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in increased toxicity (Figure 2) [15]. In this regard, the
potential involvement of peroxidases in neurodegeneration
and Parkinson’s disease has been already suggested [50–52,
62]. Myeloperoxidase occurs at sites of degenerative diseases
and neuroinflammation and increases in Alzheimer’s disease
[48, 63], and its ablation mitigated PD produced by MPTP
neurotoxin in animals [49].
MPTP and 2-methyltetrahydro-𝛽-carbolines differed in
the activation route to toxic metabolites (i.e., MAO ver-
sus heme peroxidase). However, both were metabolized
by human cytochrome P450 2D6. This enzyme carried
out the metabolism of MPTP by N-demethylation and
aromatic hydroxylation and 2-methyltetrahydro-𝛽-carboline
by aromatic hydroxylation (Figure 2). The involvement of
cytochrome P450 2D6 in detoxification is relevant, and some
studies have reported an association between cytochrome
P450 2D6 polymorphism and Parkinson’s disease (PD)
[44, 64]. This enzyme is lower in PD patients, which may
reduce the ability of those patients to inactivate PD-causing
neurotoxicity [64]. For example, exposure to pesticides
increases the incidence of PD, and this risk was even higher
in subjects with a poor metabolizer 2D6 genotype exposed
to pesticides [3, 45]. In contrast to pyridinium species (i.e.,
MPDP+ and MPP+) produced by MAO, the MPTP-OH and
PTP metabolites arising from cytochrome P450 2D6 are
thought to be devoid of neurotoxicity [12, 65]. Therefore,
cytochrome P450 2D6 competes with MAO enzymes in
favour of an inactivation route of the MPTP neurotoxin
[14]. Results in Figure 4 also showed that P450 2D6 slightly
activated MPTP to the pyridinium species, MPDP+ and
MPP+. Recently, a mitochondrial cytochrome P450 2D6 was
reported that was able to carry out the activation of MPTP
to pyridinium species (MPDP+ and MPP+) suggesting a role
for this enzyme in the activation process and toxicity [17];
however, this conversion appeared to be of lower significance
compared with MAO [14].
𝛽-Carbolines abound in plants and foods and appear in
biological tissues including the brain [25, 27, 66, 67]. They
exert psychopharmacological and behavioural effects [23–
27, 54, 66, 68]. An involvement of tetrahydro-𝛽-carbolines
(and/or 𝛽-carbolines) as proneurotoxins is based on the
fact that these compounds are N-methylated to 𝑁(2)-
methyltetrahydro-𝛽-carbolines which can be subsequently
oxidized to 𝑁(2)-methyl-𝛽-carbolinium species [20, 21, 29,
33, 69]. N-Methylation of tetrahydro-𝛽-carbolines (TH𝛽C)
is catalyzed by brain N-methyltransferases [69], and 2-
methyltetrahydro-𝛽-carboline has been detected in rat brain
[70]. However, this sequence lacks a step of activation to
𝛽-carbolinium species. 2-Methyltetrahydro-𝛽-carboline is
not neurotoxic [65] but it could be oxidized (activated) to
toxic𝛽-carboliniumcation (𝛽C+) by hemeperoxidases/H
2
O
2
(lactoperoxidase and myeloperoxidase) (Figures 2 and 6). 𝛽-
Carbolinium species resemble MPP+ in many of their tox-
icological features. N-Methyl-𝛽-carbolinium cation (2-Me-
𝛽C+) and N,N-dimethyl-𝛽-carbolinium cation (2,9-diMe-
𝛽C+) are neurotoxins producing irreversible striatal lesions
[31, 71].These carbolinium species (2-Me-𝛽C+ and 2,9-diMe-
𝛽C+) were found in normal and parkinsonian brains [34–
36] and appeared in higher proportion in the brain and
cerebrospinal fluid of PD patients [34, 35]. As the cytochrome
P450 2D6 contributes to the metabolism of tetrahydro-𝛽-
carbolines to hydroxylated metabolites [14, 43], this route
could be competitive against the oxidation by peroxidases
and the N-methylation by N-methyltransferases [14, 15, 21].
The biotransformation of 𝛽-carbolines by cytochrome P450
2D6 may influence the outcome of these substances as
eventual protoxins and generate differences depending on
enzyme polymorphism.
In summary, these results indicate that activation/inacti-
vation of MPTP and 2-methyltetrahydro-𝛽-carboline pro-
toxins depends on three key oxidative enzymes that are
crucial for toxicity and detoxification. MPTP relays on MAO
enzymes for activation (toxicity) with a possible role for heme
peroxidases. However, it relays on cytochrome P450 2D6 for
inactivation. In contrast, 2-methyltetrahydro-𝛽-carbolines
depend on heme peroxidases for activation to toxic carbolin-
ium species and cytochromeP450 2D6 for detoxificationwith
no role played byMAO enzymes. It can be concluded that the
degree of toxicity caused by those protoxins may result from
a balance between the rate of activation to toxic products (i.e.,
N-methylpyridinium—MPP+ and MPDP+—and N-methyl-
𝛽-carbolinium—𝛽C+—) and the rate of inactivation (detoxi-
fication) (i.e., N-demethylation, aromatic hydroxylation). As
the enzymes involvementmay vary in expression and activity
between persons, major differences in the toxicological out-
come of these protoxins are foreseen.
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